Press releases and announcements

Tokyo, Japan and Ghent, Belgium: October 1st, 2013 - Miraca Holdings Inc., a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, today announced that its affiliate Innogenetics N.V. will change its name to Fujirebio Europe N.V. with immediate effect. The name change is the next logical step in an integration process that was launched by the acquisition in September 2010 of Innogenetics N.V. by Fujirebio Inc., a subsidiary of Miraca Holdings.

Ghent, Belgium: November 16, 2011 - Innogenetics, an international diagnostics company that develops and markets diagnostic products to improve therapy management and patient health, announced the Italian launch of its LUMIPULSE® G1200, a fully automated chemiluminescent enzyme immunoassay (CLEIA) system, at the 1° Congresso della Medicina di Laboratorio (SIMel/SIBioC) in Parma, Italy on November 16.

Tokyo, Japan: September 24 2010 – Fujirebio, a Miraca Holdings group company, has completed the acquisition of all of the issued and outstanding shares of Innogenetics NV. The acquisition was consummated in accordance with the terms and conditions of the definitive agreement that had been referred to in Fujirebio's previous release ("Fujirebio to acquire Innogenetics from Abbott") dated July 20, 2010.

Pages

CLOSE

You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.